J&J Medical Connect
DARZALEX FASPRO®

(daratumumab and hyaluronidase-fihj)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)
Medical Information

DARZALEX FASPRO - Latex Content

Last Updated: 09/25/2026

SUMMARY  

  • DARZALEX FASPRO is supplied as a colorless to yellow and clear to opalescent preservative-free solution for subcutaneous injection and is supplied in single-dose vials.1
  • The immediate container and excipient do not contain latex/natural rubber. However, it cannot be guaranteed that the materials have not come in contact with latex during the manufacturing or packaging process (e.g., latex gloves).2

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 25 August 2026.

 

References

Show
1 Data on File. Daratumumab Subcutaneous Formulation Company Core Data Sheet (CCDS). Janssen Research & Development, LLC. EDMS-ERI-184804517; 2026.  
2 Data on File. Technical Document Patient Safety and Compliance Information. Janssen Research & Development, LLC. TV-TEC-172936; 2025.  

Would you like to clear and leave your conversation? Message history will be lost.